Journal of Pediatric Health Care
Volume 23, Issue 2 , Pages 75-89 , March 2009

Pharmacologic Treatment for the Core Deficits and Associated Symptoms of Autism in Children

  • Lis West, MS, CPNP
    • ,
  • Julee Waldrop, MS, FNP, PNP

      Affiliations

    • Corresponding Author InformationCorrespondence: Julee Waldrop, MS, FNP, PNP, The University of North Carolina, CB#7225, Chapel Hill, NC 27599
    • ,
  • Susan Brunssen, PhD, RN

References 

  1. Aman M, Van Bourgondien M, Wolford P, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:1672–1681
  2. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  3. Arnold E, Aman M, Cook A, Witwer A, Hall K, Thompson S, et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1196–1205
  4. Campbell M, Armenteros J, Malone R, Adams P, Eisenberg Z, Overall J. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;26:835–843
  5. Centers for Disease Control and Prevention . CDC releases new data on autism spectrum disorders from multiple communities in the United States (CDC Media Relations). Retrieved March 21, 2007. from http://www.cdc.gov/od/oc/media/pressrel/2007/r070208.htm2007;
  6. Eli Lilly . Zyprexa (package insert). Indianapolis, IN: Eli Lilly and Company; 2006;
  7. Elia J, Borcherding G, Rapoport J, Keysor C. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?. Psychiatry Research. 1991;36:141–155
  8. Food and Drug Administration . FDA approves the first drug to treat irritability associated with autism, Risperdal. FDA News. 2006;Retrieved December 30, 2006, from http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html
  9. Findling R, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin. 1997;33:155–159
  10. Findling R, McNamara N, Gracious B, O'Riordan M, Reed M, Demeter C, et al. Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 2004;14:287–294
  11. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders. 2003;33:365–382
  12. Greenhill L, Swanson J, Vitiello B, Davies M, Clevenger W, Wu M, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:180–187
  13. Gringras P. Practical paediatric psychopharmacological prescribing in autism: The potential and the pitfalls. Autism. 2000;4:229–247
  14. Handen B, Johnson C, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders. 2000;30:245–255
  15. Hellings J, Weckbaugh M, Nickel E, Cain S, Zarcone J, Reese M, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2005;15:682–692
  16. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–589
  17. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. International Journal of Neuropsychopharmacology. 2005;9:209–213
  18. Hollander W, Wasserman S, Swanson E, Chaplin W, Schapiro M, Zagursky K, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 2006;16:541–548
  19. King B, Wright M, Handen B, Sikich L, Zimmerman A, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:658–665
  20. Lacy C, Armstrong L, Goldman M, Lance L. Drug information handbook: A comprehensive resource for all clinicians and health care professionals. 14th ed.. Hudson, OH: Lexi-Comp, Inc; 2006;
  21. Langworthy-Lam K, Aman M, Van Bourgondien M. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology. 2002;12:311–321
  22. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders. 2006;36:1101–1114
  23. Malone R, Cater J, Sheikh R, Choudhury M, Delaney M. Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American of Child and Adolescent Psychiatry. 2001;40:887–894
  24. Malone R, Maislin G, Choudhury M, Gifford C, Delaney M. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:140–147
  25. Martin A, Koenig K, Anderson G, Scahill L. Low-dose Fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders. 2003;33:77–85
  26. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 1999;9:99–107
  27. McDougle C, Holmes J, Bronson M, Anderson G, Volkmar F, Price L, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Child and Adolescent Psychiatry. 1997;26:685–693
  28. McDougle C. Ask the Editor. Journal of Autism and Developmental Disorders. 2004;34:593–594
  29. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry. 2005;162:1142–1148
  30. Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2006;16:517–524
  31. Owley T, Walton L, Salt J, Guter S, Winnega M, Leventhal B, et al. An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:343–348
  32. Perry R, Pataki C, Munoz-Silva D, Armenteros J, Silva R. Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology. 1997;7:167–179
  33. Posey D, Erickson C, Stigler K, McDougle C. The use of serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology. 2006;16:181–186
  34. Posey D, Wiegand R, Wilkerson J, Maynard M, Stigler K, McDougle C. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with higher-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2006;16:599–610
  35. Research Units on Pediatric Psychopharmacology Autism Network . Risperidone in children with autism and serious behavioral problem. New England Journal of Medicine. 2002;347:314–321
  36. Research Units on Pediatric Psychopharmacology Autism Network . Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry. 2005;162:1361–1369
  37. Research Units on Pediatric Psychopharmacology Autism Network . Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry. 2005;62:1266–1274
  38. Scahill L, Aman M, McDougle M, McCracken J, Tierney E, Dziura J, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2006;16:589–598
  39. Scahill L, Chappell P, Kim Y, Schultz R, Katsovich L, Shepherd E, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention-deficit hyperactivity disorder. American Journal of Psychiatry. 2001;158:1067–1074
  40. Taketomo CK, Taketomo C, Hodding JH, Kraus DM. Lexi-Comp's pediatric dosage handbook. 13th ed.. Hudson, OH: Lexi-Comp Inc; 2006;
  41. Wasserman S, Iyengar R, Chaplin W, Watner D, Waldoks S, Anagnostou E, et al. Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology. 2006;21:363–367
  42. West L, Waldrop J. Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatric Nursing. 2006;32:545–549

PII: S0891-5245(08)00394-5

doi: 10.1016/j.pedhc.2008.12.001

Journal of Pediatric Health Care
Volume 23, Issue 2 , Pages 75-89 , March 2009

Article Tools